

Pazopanib COMPARZ

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects



Less serious adverse events observed


Other adjustments



Pazopanib COMPARZ

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease
Experimental Arm: Pazopanib
Control Arm: Sunitinib

